Uniqure NVNASDAQ:QURE
- LAST PRICE6.0800
- TODAY'S CHANGE (%)-0.1000 (-1.6181%)
- Bid / Lots6.0400/ 7
- Ask / Lots6.0800/ 7
- Open / Previous Close6.0700 / 6.1800
- Day Range
- 52 Week Range
- Volume46,276
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | QURE |
|---|---|---|
| 09:32 ET | 3290 | 6.12 |
| 09:33 ET | 700 | 6.045 |
| 09:35 ET | 1000 | 6.01 |
| 09:37 ET | 2686 | 5.95 |
| 09:39 ET | 2325 | 5.955 |
| 09:42 ET | 1221 | 6.02 |
| 09:44 ET | 1557 | 6.06 |
| 09:46 ET | 400 | 6.02 |
| 09:48 ET | 700 | 6.01 |
| 09:50 ET | 950 | 6.01 |
| 09:53 ET | 925 | 6.015 |
| 09:55 ET | 1028 | 6.05 |
| 09:57 ET | 500 | 6.0182 |
| 10:00 ET | 800 | 6.02 |
| 10:02 ET | 1550 | 6.035 |
| 10:04 ET | 1000 | 6.045 |
| 10:06 ET | 6766 | 6 |
| 10:08 ET | 3295 | 6.02 |
| 10:09 ET | 1761 | 6.08 |
Nov 6, 2024
DJ uniQure Price Target Maintained With a $25.00/Share by HC Wainwright & Co., from 2:04PM ET on Wednesday Nov 06, 2024 by Dow Jones
2:04PM ET on Wednesday Nov 06, 2024 by Dow JonesDJ uniQure Is Maintained at Neutral by Goldman Sachs, from 12:40PM ET on Wednesday Nov 06, 2024 by Dow Jones
12:40PM ET on Wednesday Nov 06, 2024 by Dow JonesDJ uniQure Is Maintained at Outperform by RBC Capital, from 12:22PM ET on Wednesday Nov 06, 2024 by Dow Jones
12:22PM ET on Wednesday Nov 06, 2024 by Dow JonesDJ uniQure Price Target Maintained With a $28.00/Share by Cantor Fitzgerald, from 9:52AM ET on Wednesday Nov 06, 2024 by Dow Jones
9:52AM ET on Wednesday Nov 06, 2024 by Dow Jones
Nov 5, 2024
*DJ uniQure 3Q Loss/Shr 91c >QURE, from 7:05AM ET on Tuesday Nov 05, 2024 by Dow Jones
7:05AM ET on Tuesday Nov 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Uniqure NV | 301.2M | -1.2x | --- |
Iteos Therapeutics Inc | 287.8M | -2.5x | --- |
C4 Therapeutics Inc | 296.5M | -2.4x | --- |
AC Immune SA | 310.2M | -6.9x | --- |
Absci Corp | 314.6M | -2.7x | --- |
Molecular Partners AG | 234.1M | -2.9x | --- |
Company Information
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
Contact Information
- Headquarters
- Paasheuvelweg 25aAMSTERDAM, Netherlands 1105 BP
- Phone
- ---
- Fax
- ---
Executives
- Non-Executive Independent Chairman of the Board
- David Meek
- Chief Executive Officer, Executive Director
- Matthew Kapusta
- Chief Financial Officer
- Christian Klemt
- Chief Technical Operations Officer
- Amin Abujoub
- Chief Business and Scientific Officer
- Richard Porter
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $301.2M |
|---|---|
Revenue (TTM) | $28.6M |
Shares Outstanding | 48.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.90 |
EPS | $-4.96 |
Book Value | $4.34 |
P/E Ratio | -1.2x |
Price/Sales (TTM) | 10.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -700.37% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
